No Detail Found!

Outcomes of Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

Author(s)
Nasir Ahmad Chaudhry Department of Ophthalmology, Eye Unit 2 Mayo Hospital, Lahore, Pakistan
Sarmad Zahoor Department of Ophthalmology, Eye Unit 2 Mayo Hospital, Lahore, Pakistan
Usama Iqbal Department of Ophthalmology, DHQ Teaching Hospital, Gujranwala, Pakistan
Muhammad Owais Sharif Department of Ophthalmology, Eye Unit 3 Mayo Hospital, Lahore, Pakistan
Muhammad Sharjeel Department of Ophthalmology, Gomal Medical College, DI Khan – KPK, Pakistan
Asima Rafique Department of Ophthalmology, Eye Unit 3 Mayo Hospital, Lahore, Pakistan
Abstract
Purpose: To determine the functional and anatomical outcome of intravitreal Bevacizumab in patients with macular edema secondary to branch retinal vein occlusion. Study Design: Quasi Experimental study. Material and Methods: Forty eyes of 40 patients with macular edema on OCT (macular thickness > 300 µm) secondary to BRVO were included in the study. All the patients suffering from other types of macular edema caused by diabetes, epi-retinal membrane (ERM), surgery involving posterior segment, vitreoretinal traction and history of intravitreal VEGF or steroids were excluded from the study. Intravitreal Bevacizumab was given when macular thickness was > 300 µm or Visual acuity was < 6/12. Follow-up was at 1st, 3rd, 6th and 12th month. Results: The mean age of the patients was 52.12 ± 5.63 years. Male to female ratio was 1.5:1. Infero-temporal venous arcade was the most common site of BRVO (55%) followed by supero-temporal (35%) and macular BRVO (10%). Baseline visual acuity was 6/12 or better in 17.5% of the patients at presentation. This proportion increased to 27.5%, 40%, 52.5% and 67.5% at 1, 3, 6 and 12 months respectively. Macular thickness measured at presentation was 540 ± 120 µm. Macular thickness gradually reduced on follow-up. At one month mean macular thickness was 430 ± 90 µm. It was less than 300 µm after 6 months. Conclusion: Intravitreal bevacizumab results in improved functional and anatomical outcomes in cases of macular edema secondary to BRVO.
Publication Details
Page(s) 231-235
Published Journal: Pakistan Journal of Ophthalmology , Volume: 36, Issue: 3, Year: 2020

Request the full text from PASTIC

0

Citations

0

Downloads

92

Views